Natpara

GPTKB entity

Properties (56)
Predicate Object
gptkbp:instanceOf drug
gptkbp:activeDuring gptkb:parathyroid_hormone
gptkbp:administrativeDivision subcutaneous injection technique
gptkbp:applicationStatus covered by many insurance plans
gptkbp:brand gptkb:Natpara
gptkbp:clinicalTrials Phase 3
ongoing studies
improves quality of life
long-term management
recommended for hypoparathyroidism
gptkbp:community_service available
gptkbp:contraindication allergic reactions
hypercalcemia
hypersensitivity to the drug
hypocalcemia
gptkbp:customerFeedback generally positive
gptkbp:date 2015-01-23
gptkbp:dosageForm injectable solution
gptkbp:drugInterdiction available online
none reported
subcutaneous absorption
half-life of 2 hours
increases bone turnover
increases serum calcium
specialist only
gptkbp:formulation lyophilized powder
gptkbp:hasPopulation adults
pediatric patients
gptkbp:healthcare available resources
important for effectiveness
injection technique
signs of low calcium
https://www.w3.org/2000/01/rdf-schema#label Natpara
gptkbp:is_monitored_by kidney function
calcium levels
gptkbp:launchSite once daily
gptkbp:mandates treatment of low calcium levels
gptkbp:manufacturer gptkb:NPS_Pharmaceuticals
gptkbp:marineSafety available for eligible patients
gptkbp:market US_market
gptkbp:marketSegment available
gptkbp:offers varies by pharmacy
gptkbp:packaging single-use vial
gptkbp:regulatoryCompliance FDA_approved
gptkbp:renovated requires sterile water
gptkbp:research supported by grants
gptkbp:research_areas hormones
gptkbp:researchInterest published in medical journals
gptkbp:route subcutaneous injection
gptkbp:safetyFeatures generally well tolerated
gptkbp:sideEffect headache
nausea
injection site reactions
gptkbp:storage refrigerated
gptkbp:triggerType replaces parathyroid hormone
gptkbp:usedFor hypoparathyroidism